Kiora and Théa Open Innovation Enter Partnership to Develop and Commercialize KIO-301
Read more
Contact MENU

News

Showing posts for — Category: Press Releases

11.07.19

EyeGate Pharma Reports Third Quarter 2019 Financial Results and Provides Business Update

WALTHAM, MA, November 7, 2019 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced...
Read more
10.09.19

EyeGate Pharma Enrolls First Patient in Follow-on PE Pilot Study

WALTHAM, MA, October 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
10.09.19

EyeGate Pharma Completes Randomization in Pivotal Study

WALTHAM, MA, October 9, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
09.30.19

EyeGate Enters Into Agreement for $1.9 Million Private Placement

WALTHAM, MA, September 30, 2019 – EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG), (“EyeGate” or the “Company”), a clinical-stage company focused on developing products for treating disorders of the eye, today announced that it has...
Read more
09.23.19

EyeGate Pharma Regains Nasdaq Listing Compliance

WALTHAM, Mass., Sept. 23, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
09.20.19

EyeGate Pharma Reaches 75% Randomization of Patients in Pivotal Study

WALTHAM, Mass., Sept. 16, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
09.03.19

EyeGate Pharma to Present at H.C. Wainwright 21st Annual Global Investment Conference

WALTHAM, Mass., September 3, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more
08.29.19

EyeGate Pharma Announces Reverse Stock Split Effective August 30, 2019

WALTHAM, MA, August 29, 2019 (ACCESSWIRE) — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced...
Read more